NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Bioaffinity Technologies, Inc. BIAF
5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$6.2M
▼ 34.2% vs FY2024
EPS · FY25
$-8.66
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-301.8%
Net margin · FY25
-242.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6.2M
Revenue, FY2025 · full 5-year series below
Revenue
Net income
The company lost 242 cents on every revenue dollar this year.
Per share
USD -8.66
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-301.8%
Return on equity, FY2025
ROE
Operating margin-171.6%
Net margin-242.0%
Return on assets-170.6%
Each USD of equity lost 302 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+986.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 11.0M
total assets, end of FY2025
Total assetsUSD 11.0M
EquityUSD 7.3M
CashUSD 6.4M
Current ratio2.60×
Equity funds 66% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−8.66
−22.50
−0.91
−1.81
·
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−301.8
−242.4
−99.8
·
·
Shares out B
0.00
0.00
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed